The benefits of the GLP-1 receptor agonists are now recognised to extend beyond improving glycaemic control and effecting weight loss in patients with type 2 diabetes. Take chronic kidney disease for example.

In this panel discussion, nephrologist, Professor Eugenia Pedagogos and endocrinologist, Professor Richard MacIsaac will be asked about the evidence for and role of GLP-1 receptor agonists in the prevention and management of kidney disease in patients with type 2 diabetes and will provide practical advice for clinicians wanting to offer this treatment option to their diabetic patients.

<p>The benefits of the GLP-1 receptor agonists are now recognised to extend beyond improving glycaemic control and effecting weight loss in patients with type 2 diabetes. Take chronic kidney disease for example.</p>
<p>In this panel discussion, nephrologist, Professor Eugenia Pedagogos and endocrinologist, Professor Richard MacIsaac will be asked about the evidence for and role of GLP-1 receptor agonists in the prevention and management of kidney disease in patients with type 2 diabetes and will provide practical advice for clinicians wanting to offer this treatment option to their diabetic patients.</p>

Audio versions of Healthed Webcasts, designed for the busy healthcare professional.

Advertisement